Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.15
Bid: 3.00
Ask: 3.30
Change: 0.025 (0.80%)
Spread: 0.30 (10.00%)
Open: 3.125
High: 3.20
Low: 3.125
Prev. Close: 3.125
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Head of Clinical Science

4 Nov 2014 07:00

RNS Number : 0390W
Allergy Therapeutics PLC
04 November 2014
 



4 November 2014

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Appointment of Dr Daphne Tsitoura as Head of Clinical Science

 

 

Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces the appointment of Dr Daphne Tsitoura as Head of Clinical Science leading the Clinical Development team in Munich and Worthing from the 10th November, reporting to Professor Tim Higgenbottam.

 

Dr Tsitoura joins Allergy Therapeutics from GSK, where she has spent the last eight years as Principal Physician in the Respiratory Therapeutic Area in the GSKs' Stevenage Research Centre UK and has maintained a clinical link with allergy as an associate Allergist at University College Hospital London UK.

 

Previously she has held roles of Principal Immunologist at the Institute of Biomedical Research Academy of Athens, Consultant Physician / Chief of the Allergy Unit at the Henry Dunant Hospital Athens, senior fellow in immunology and allergy at Stanford University School of Medicine Palo Alto USA, and associate professor in Respiratory Medicine College of Physicians and Surgeons Columbia University New York.

 

Tim Higenbottam, R & D Director said:

 

"With an impressive career in medicine development and allergy, Daphne brings to Allergy Therapeutics a passion and drive to enhance the ease of use of allergy vaccines. She has a great depth of understanding of the therapeutic methods of modulation of the innate immune system to optimise allergy therapies. Her expertise will lend enormous support and strengthen our team of pharmaceutical experts and drive the research to gain approval of our Pollinex Quattro ultra-short course allergy vaccines in Europe and US."

 

 

-Ends-

 

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Peel Hunt LLP

+44 (0) 20 7418 8900

James Steel / Clare Terlouw

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Victoria Foster Mitchell / Mo Noonan

 

 

Notes to editors

 

About Allergy Therapeutics

 

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with revenue of £42million achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAXFDEFELFFF
Date   Source Headline
7th May 20247:00 amRNSFurther detail from G306 Phase III field trial
3rd Apr 20247:00 amRNSDirector Resignation
27th Mar 20247:00 amRNSUpdate on funding
27th Mar 20247:00 amRNSInterim Results for six months ended 31 Dec 2023
12th Mar 20248:59 amRNSVLP Peanut PROTECT Trial Update
12th Mar 20247:00 amRNSVLP Peanut PROTECT Trial Update
11th Mar 20247:00 amRNSAppointment of Shaun Furlong to Board of Directors
8th Mar 20241:49 pmRNSResult of AGM
14th Feb 20247:00 amRNSHalf-Year Trading Update 2024
9th Feb 20243:07 pmRNSNotice of 2023 Annual General Meeting
30th Jan 20247:30 amRNSRestoration - Allergy Therapeutics plc
30th Jan 20247:00 amRNSPublication of Annual Report and Accounts 2023
4th Jan 202412:29 pmRNSTotal Voting Rights
2nd Jan 20247:30 amRNSSuspension - Allergy Therapeutics plc
27th Dec 202312:01 pmRNSAmendment to existing Facility Agreement
15th Dec 202312:48 pmRNSAnnual Report and Accounts Delayed
13th Dec 20234:54 pmRNSPDMR dealing and Total Voting Rights
13th Dec 20237:00 amRNSG306 Phase III trial meets key endpoints
11th Dec 20237:00 amRNSUpdate on funding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20233:03 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSG306 Grass Phase III trial meets primary endpoint
10th Nov 20232:39 pmRNSForm 8.5 (EPT/RI)
10th Nov 20231:22 pmRNSDirector/PCA Dealing
10th Nov 20231:11 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSOffer Closure
9th Nov 202310:48 amRNSExercise of Options and Total Voting Rights
9th Nov 20239:24 amRNSForm 8.5 (EPT/RI)
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202310:45 amRNSForm 8.5 (EPT/RI)
7th Nov 202311:10 amRNSForm 8.5 (EPT/RI)
6th Nov 20239:33 amRNSForm 8.5 (EPT/RI)
6th Nov 20237:00 amRNSUpdate on funding
3rd Nov 20239:31 amRNSForm 8.5 (EPT/RI)
2nd Nov 202310:24 amRNSForm 8.5 (EPT/RI)
1st Nov 202310:23 amRNSForm 8.5 (EPT/RI)
31st Oct 20238:30 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:06 amRNSForm 8.5 (EPT/RI)
27th Oct 202311:33 amRNSForm 8.5 (EPT/RI)
26th Oct 202310:07 amRNSForm 8.5 (EPT/RI)
25th Oct 20239:48 amRNSForm 8.5 (EPT/NON-RI)
25th Oct 20238:43 amRNSForm 8.5 (EPT/RI)
24th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
23rd Oct 20238:23 amRNSForm 8.5 (EPT/RI)
20th Oct 20235:17 pmRNSHolding(s) in Company
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.